Molecular Templates to Participate in Two May Virtual Investor Conferences

AUSTIN, Texas, May 13, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced that management will participate in the Bank of America Securities Virtual Healthcare Conference and the UBS Virtual Healthcare Conference.

Bank of America Securities Virtual Healthcare Conference
Date:   May 14
     
UBS Virtual Healthcare Conference
Date:   May 18
Presentation Time:   9:10am Eastern Time
Webcast:   Click here for webcast
     

About Molecular Templates 
Molecular Templates is a clinical-stage company focused on the discovery and development of targeted biologic therapeutics. Molecular Templates’ proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases.

Investor Contact:

Adam Cutler
Chief Financial Officer
adam.cutler@mtem.com
862-204-4006

Source: Molecular Templates, Inc.

molecular.jpg

Source: Molecular Templates, Inc.